Orphan Drug Designation Given to New Mesothelioma CAR T-Cell Therapy
In early 2023, the world-class Hospital of the University of Pennsylvania will open a groundbreaking clinical trial for mesothelioma patients utilizing a next-generation immunotherapy with a novel delivery platform. The U.S. Food and Drug Administration cleared the path in September by granting orphan drug designation for SynKIR-110, a CAR T-cell therapy designed to target solid tumors expressing a specific protein typically found in mesothelioma cancer. By granting the orphan drug designation, the FDA can provide financial incentives such as tax credits for clinical trials and seven years of market exclusivity. It i...
Source: Asbestos and Mesothelioma News - October 5, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news

Fertility Preservation for Women With Breast Cancer Fertility Preservation for Women With Breast Cancer
How do alternative ovarian stimulation protocols for women with breast cancer compare to standard ovarian stimulation in terms of COC yield?Human Reproduction (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2022 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer
(MedPage Today) -- NEW YORK -- Rucaparib (Rubraca) turned in mixed results for survival outcomes in patients with recurrent ovarian carcinoma, according to an ARIEL3 trial update. There was a benefit for progression-free survival (PFS), as treatment... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 2, 2022 Category: Hematology Source Type: news

'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer
(MedPage Today) -- NEW YORK -- A post-hoc analysis of overall survival (OS) in the SOLO3 trial demonstrated why olaparib (Lynparza) recently had its fourth-line indication in ovarian cancer pulled by drugmaker AstraZeneca. The phase III trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 1, 2022 Category: Hematology Source Type: news

Consumer Health: What is your risk of ovarian cancer?
September is Ovarian Cancer Awareness Month, which makes this a good time to learn about your risk of developing ovarian cancer. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and ranks fifth in cancer deaths among women in the U.S., according to the American Cancer Society. More than 19,000 new cases will be diagnosed in the U.S. this year, and nearly 13,000 women will die of the disease. Ovarian cancer is… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 29, 2022 Category: Databases & Libraries Source Type: news

U.S. Court of Appeals Hears Challenge to J & J ’s Bankruptcy Plan
Johnson & Johnson’s controversial bankruptcy filing, designed to limit its soaring talc liabilities, was challenged Sept. 26 before the United States Court of Appeals for the Third Circuit in Philadelphia. A three-judge panel heard oral arguments on whether Johnson & Johnson should be permitted to shift billions of dollars in mass tort liabilities to a newly created entity, which immediately filed for bankruptcy. The court’s decision is not expected until later in 2022. Regardless of the outcome, several legal experts believe yet another appeal will be filed with the U.S. Supreme Court. Attorneys repre...
Source: Asbestos and Mesothelioma News - September 28, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news

Machine learning creates opportunity for new personalized therapies
Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism. (Source: World Pharma News)
Source: World Pharma News - September 28, 2022 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Mayo Clinic's Fergus Couch, Ph.D., awarded Basser Global Prize for BRCA Research
ROCHESTER, Minn. — The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania has awarded Mayo Clinic's Fergus Couch, Ph.D., with the 10th annual Basser Global Prize. This highly distinguished award recognizes a leading scientist who has advanced research related to BRCA1 and BRCA2 genes. People with mutations in these genes are at an increased risk of breast, ovarian, pancreatic and prostate cancers. Dr. Couch is chair of the Division… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 28, 2022 Category: Databases & Libraries Source Type: news

Preventing Doxorubicin-Induced Hand-Foot Syndrome Preventing Doxorubicin-Induced Hand-Foot Syndrome
Dexamethasone plus wrist and ankle cooling may prevent hand-foot syndrome from doxorubicin in patients with ovarian cancer. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Drug Companies Withdraw PARPi Indications for Ovarian Cancer Drug Companies Withdraw PARPi Indications for Ovarian Cancer
Zejula, Lynparza, and Rubraca have been voluntarily withdrawn for late-line ovarian cancer treatment indications over concerns surrounding an increased risk for death.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Asbestos Health Screenings in Libby, Montana, Expanding
Highly specialized asbestos exposure health screenings in Libby, Montana, have gone mobile. In an effort to identify lung abnormalities at their earliest stage, the groundbreaking Center for Asbestos Related Disease – known as CARD – has begun touring the state, offering its services to those unable or unwilling to travel. The efforts have been well received. Libby is a small town in rural northwest Montana that is home to one of the largest human-made environmental disasters and longest-running asbestos cleanup project in American history. Although restoration is all but complete in the scenic and charming...
Source: Asbestos and Mesothelioma News - September 20, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Asbestos Exposure Mesothelioma Source Type: news

Reassuring Data: Olaparib Dose Reductions Have Minimal Effect Reassuring Data: Olaparib Dose Reductions Have Minimal Effect
Dr Maurie Markman discusses a recent paper describing olaparib interruptions and dose reductions in ovarian cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Asbestos Found in Talc-Based Tiger Brands Baby Powder
Johnson & Johnson isn’t the only market leader struggling with the issue of asbestos-contaminated talc in its baby powder. Tiger Brands, the largest food producer in South Africa, has recalled its Purity Essentials Baby Powder as a “precautionary measure,” after trace amounts of asbestos were detected in test samples. The recall was announced Sept. 8, less than a month after Johnson & Johnson informed company shareholders that it was ending the worldwide sale of its talc-based product in 2023. Tiger Brands, one of the largest packaged goods companies on the continent, is expected to continue selling ...
Source: Asbestos and Mesothelioma News - September 14, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Asbestos Exposure Source Type: news

Ovarian Cancer Is Not Silent: Common, Nonspecific Symptoms Ovarian Cancer Is Not Silent: Common, Nonspecific Symptoms
Dr Maurie Markman discusses a recent publication on the symptoms of early-stage, high-risk ovarian cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Denosumab Halts Bone Loss From Ovarian Suppression, AIs for Breast Cancer
(MedPage Today) -- AUSTIN, Texas -- The profound bone loss often experienced by women with early-stage breast cancer on ovarian function suppression and aromatase inhibitor (AI) therapy to prevent cancer recurrence appeared to be prevented with... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 13, 2022 Category: Endocrinology Source Type: news